Literature DB >> 26787170

Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.

Rotraut Mössner1, Nina Diering1, Oliver Bader2, Susann Forkel1, Tobias Overbeck3, Uwe Gross2, Bodo Grimbacher4, Michael P Schön1, Timo Buhl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26787170     DOI： 10.1093/cid/ciw020

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  30 in total

Review 1.  What Is the Cause of the Chronic Erythematous Scaling Plaques on This 22-Month-Old Girl and Her Family?

Authors:  Teresa Ro; Amika Sood; Kevin J Kelly; Dean S Morrell
Journal:  Clin Pediatr (Phila)       Date:  2017-10-30       Impact factor: 1.168

Review 2.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

3.  Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.

Authors:  Katja G Weinacht; Louis-Marie Charbonnier; Fayhan Alroqi; Ashley Plant; Qi Qiao; Hao Wu; Clement Ma; Troy R Torgerson; Sergio D Rosenzweig; Thomas A Fleisher; Luigi D Notarangelo; Imelda C Hanson; Lisa R Forbes; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2017-01-27       Impact factor: 10.793

4.  Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Authors:  Alexander Vargas-Hernández; Emily M Mace; Ofer Zimmerman; Christa S Zerbe; Alexandra F Freeman; Sergio Rosenzweig; Jennifer W Leiding; Troy Torgerson; Matthew C Altman; Edith Schussler; Charlotte Cunningham-Rundles; Ivan K Chinn; Alexandre F Carisey; Imelda C Hanson; Nicholas L Rider; Steven M Holland; Jordan S Orange; Lisa R Forbes
Journal:  J Allergy Clin Immunol       Date:  2017-10-27       Impact factor: 10.793

Review 5.  Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.

Authors:  Satoshi Okada; Takaki Asano; Kunihiko Moriya; Stephanie Boisson-Dupuis; Masao Kobayashi; Jean-Laurent Casanova; Anne Puel
Journal:  J Clin Immunol       Date:  2020-08-27       Impact factor: 8.317

6.  Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.

Authors:  Julie Toubiana; Satoshi Okada; Julia Hiller; Matias Oleastro; Macarena Lagos Gomez; Juan Carlos Aldave Becerra; Marie Ouachée-Chardin; Fanny Fouyssac; Katta Mohan Girisha; Amos Etzioni; Joris Van Montfrans; Yildiz Camcioglu; Leigh Ann Kerns; Bernd Belohradsky; Stéphane Blanche; Aziz Bousfiha; Carlos Rodriguez-Gallego; Isabelle Meyts; Kai Kisand; Janine Reichenbach; Ellen D Renner; Sergio Rosenzweig; Bodo Grimbacher; Frank L van de Veerdonk; Claudia Traidl-Hoffmann; Capucine Picard; Laszlo Marodi; Tomohiro Morio; Masao Kobayashi; Desa Lilic; Joshua D Milner; Steven Holland; Jean-Laurent Casanova; Anne Puel
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

7.  Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.

Authors:  Markéta Bloomfield; Veronika Kanderová; Zuzana Paračková; Petra Vrabcová; Michael Svatoň; Eva Froňková; Martina Fejtková; Radana Zachová; Michal Rataj; Irena Zentsová; Tomáš Milota; Adam Klocperk; Tomáš Kalina; Anna Šedivá
Journal:  J Clin Immunol       Date:  2018-06-22       Impact factor: 8.317

Review 8.  The Impact of Immunodeficiency on NK Cell Maturation and Function.

Authors:  Alexander Vargas-Hernández; Lisa R Forbes
Journal:  Curr Allergy Asthma Rep       Date:  2019-01-19       Impact factor: 4.806

9.  Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease.

Authors:  Ofer Zimmerman; Berenice Rösler; Christa S Zerbe; Lindsey B Rosen; Amy P Hsu; Gulbu Uzel; Alexandra F Freeman; Elizabeth P Sampaio; Sergio D Rosenzweig; Hye Sun Kuehn; Tiffany Kim; Kristina M Brooks; Parag Kumar; Xiaowen Wang; Mihai G Netea; Frank L van de Veerdonk; Steven M Holland
Journal:  Open Forum Infect Dis       Date:  2017-09-22       Impact factor: 3.835

10.  ZNF341 controls STAT3 expression and thereby immunocompetence.

Authors:  Stefanie Frey-Jakobs; Julia M Hartberger; Manfred Fliegauf; Claudia Bossen; Magdalena L Wehmeyer; Johanna C Neubauer; Alla Bulashevska; Michele Proietti; Philipp Fröbel; Christina Nöltner; Linlin Yang; Jessica Rojas-Restrepo; Niko Langer; Sandra Winzer; Karin R Engelhardt; Cristina Glocker; Dietmar Pfeifer; Adi Klein; Alejandro A Schäffer; Irina Lagovsky; Idit Lachover-Roth; Vivien Béziat; Anne Puel; Jean-Laurent Casanova; Bernhard Fleckenstein; Stephan Weidinger; Sara S Kilic; Ben-Zion Garty; Amos Etzioni; Bodo Grimbacher
Journal:  Sci Immunol       Date:  2018-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.